DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
3 clinical-grade skincare creams you really shouldn’t buy online 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Apple Restores Telegram to App Store After Content Policy Violation 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Novo Nordisk (CSE: NOVOb, NYSE: NVO) raised its full-year 2025 guidance after stronger-than-expected demand for its blockbuster weight-loss drugs helped improve its earnings outlook. The Danish pharmaceutical company now expects annual sales and operating profit to decline by no more than 6% at constant exchange rates, an improvement from its previous forecast of a 4% to 12% decline.
Despite the upgraded outlook, Novo Nordisk shares fell sharply as investors reacted to weaker-than-expected sales of the new oral version of Wegovy and disappointing clinical trial results for its experimental obesity treatment, CagriSema. U.S.-listed shares dropped about 6% on Tuesday, while Copenhagen-listed stock declined more than 4% in early Wednesday trading.
During the second quarter, oral Wegovy generated sales of 3.2 billion Danish kroner (around $500 million), slightly below analysts’ expectations of 3.3 billion kroner. Meanwhile, the injectable version of Wegovy remained the company’s top performer, delivering 19.48 billion kroner in quarterly revenue.
Investor sentiment was also pressured by new trial data showing CagriSema lagged Eli Lilly’s tirzepatide in blood sugar control among patients with Type 2 diabetes. While CagriSema met the primary goal of demonstrating noninferior weight loss, with patients losing an average of 15.2% of body weight compared with 15.8% for tirzepatide, it failed to match its rival in reducing HbA1c levels. CagriSema lowered HbA1c by 1.9%, versus 2.2% achieved by tirzepatide.
Market analysts noted the results were weaker than expected, particularly because Novo Nordisk had aimed to demonstrate noninferiority across both primary endpoints. The outcome strengthens Eli Lilly’s competitive position in the rapidly expanding obesity and diabetes treatment market.
Novo Nordisk reported second-quarter adjusted sales of 78.49 billion Danish kroner, up 7% from a year earlier. Adjusted operating profit, a key metric for investors, increased 11% to 33.39 billion kroner, while net profit declined 21% to 20.99 billion kroner.
Although demand for Wegovy continues to support Novo Nordisk’s business, investors remain focused on pipeline performance and intensifying competition in the global weight-loss drug market.
